Anti-IL-23 antibodies, compositions, methods and uses

• US 9,096,667 B2
• Filed: 08/16/2013
• Issued: 08/04/2015
• Est. Priority Date: 06/30/2005
• Status: Active Grant

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Benson, Jacqueline, Cunningham, Mark, Duchala, Cynthia, Giles-Komar, Jill M., Luo, Jinquan, Rycyzyn, Michael A., Sweet, Raymond
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US13/968,942
• Publication Number:
  US 20140046031A1
• Time in Patent Office: 718 Days
• Field of Search: 530/387.1, 530/387.3, 530/388.1, 530/388.23
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/55527 Interleukins
• CPC Class Codes: A61K 2039/55544 Bacterial toxins
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/30 characterized by aspects of specificity or valency
• CPC Class Codes: C07K 2317/33 : Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 : Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 : variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 : Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2319/55 : containing a fusion with a toxin, e.g. diphteria toxin
• CPC Class Codes: G01N 2333/54 : Interleukins [IL]
• CPC Class Codes: G01N 33/6869 : Interleukin
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Claims

1. An isolated IL-23p19 antibody, comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO;

19;

a CDRL2 amino acid sequence of SEQ ID NO;

20; and

a CDRL3 amino acid sequence of SEQ ID NO;

21,

and said heavy chain variable region comprising;

a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO;

14;

a CDRH2 amino acid sequence of SEQ ID NO;

15; and

a CDRH3 amino acid sequence of SEQ ID NO;

16.

2. An isolated IL-23p19 antibody, comprising a light chain variable region amino acid sequence of SEQ ID NO:

18.

4. An isolated IL-23p19 antibody, comprising the light chain variable region of claim 2 and a heavy chain variable amino acid sequence of SEQ ID NO:

13.

3. An isolated IL-23p19 antibody, comprising a heavy chain variable region amino acid sequence of SEQ ID NO:

13.

5. An isolated IL-23p19 antibody that competitively binds to the IL-23p19 subunit of human IL-23 with an antibody comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO;

19;

a CDRL2 amino acid sequence of SEQ ID NO;

20; and

a CDRL3 amino acid sequence of SEQ ID NO;

21,

and said heavy chain variable region comprising;

a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO;

14;

a CDRH2 amino acid sequence of SEQ ID NO;

15; and

a CDRH3 amino acid sequence of SEQ ID NO;

16.

6. The isolated antibody of claim 5, wherein said antibody is selected from the group consisting of chimeric, humanized, and CDR-grafted.

7. An isolated IL-23p19 antibody that competitively binds to the IL-23p19 subunit of human IL-23 with an antibody comprising a light chain variable region of SEQ ID NO:

18 and a heavy chain variable amino acid sequence of SEQ ID NO;

13.

8. The isolated antibody of claim 7, wherein said antibody is selected from the group consisting of chimeric, humanized, and CDR-grafted.